Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance - Archive ouverte HAL Access content directly
Journal Articles European Journal of Medicinal Chemistry Year : 2023

Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance

Abstract

Antimicrobial resistance (AMR) is a major public health issue, causing 5 million deaths per year. Without any action plan, AMR will be in a near future the leading cause of death ahead of cancer. AMR comes from the ability of bacteria to rapidly develop and share resistance mechanisms towards current antibiotics, rendering them less effective. To circumvent this issue and avoid the phenomenon of cross-resistance, new antibiotics acting on novel targets or with new modes of action are required. Today, the pipeline of potential new treatments with these characteristics includes promising compounds such as gepotidacin, zoliflodacin, ibezapolstat, MGB-BP-3, CRS-3123, afabicin and TXA-709, which are currently in clinical trials, and lefamulin, which has been recently approved by FDA and EMA. In this review, we report the chemical synthesis, mode of action, structure-activity relationships, in vitro and in vivo activities as well as clinical data of these eight small molecules listed above.
Fichier principal
Vignette du fichier
RuggierietAl_EJMC_2023.pdf (2.37 Mo) Télécharger le fichier
Origin Files produced by the author(s)
Licence
Copyright

Dates and versions

hal-04093378 , version 1 (10-05-2023)

Licence

Copyright

Identifiers

Cite

Francesca Ruggieri, Nina Compagne, Kevin Antraygues, Maxime Eveque, Marion Flipo, et al.. Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance. European Journal of Medicinal Chemistry, 2023, 256, pp.115413. ⟨10.1016/j.ejmech.2023.115413⟩. ⟨hal-04093378⟩
24 View
197 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More